Elevated plasma orexin A levels in a subgroup of patients with schizophrenia associated with fewer negative and disorganized symptoms

Psychoneuroendocrinology

Volumn 53, Issue , 2015, Pages 1-9

  Chien, Yi Ling ^a,b   Liu, Chih Min ^a,b   Shan, Jia Chi ^a,b,c   Lee, Hsin Jung ^a   Hsieh, Ming H ^a,b   Hwu, Hai Gwo ^a,b   Chiou, Lih Chu ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

Antipsychotics; Neurocognition; Orexin; Schizophrenia; Weight gain

Indexed keywords

NEUROLEPTIC AGENT; OREXIN A; NEUROPEPTIDE; OREXINS; SIGNAL PEPTIDE;

ADULT; ARTICLE; CAUSAL ATTRIBUTION; CONTROLLED STUDY; DISEASE ASSOCIATION; EXECUTIVE FUNCTION; FEMALE; HEBEPHRENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RADIOIMMUNOASSAY; SCHIZOPHRENIA; SYMPTOM ASSESSMENT; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WISCONSIN CARD SORTING TEST; ATTENTION; BLOOD; CASE CONTROL STUDY; COGNITION; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION; CASE-CONTROL STUDIES; COGNITION; EXECUTIVE FUNCTION; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NEUROPEPTIDES; NEUROPSYCHOLOGICAL TESTS; RADIOIMMUNOASSAY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84922775526     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2014.12.012     Document Type: Article

References (67)

1. Adamantidis A., de Lecea L. The hypocretins as sensors for metabolism and arousal. J. Physiol. 2009, 587:33-40.
2. Allard J.S., Tizabi Y., Shaffery J.P., Trouth C.O., Manaye K. Stereological analysis of the hypothalamic hypocretin/orexin neurons in an animal model of depression. Neuropeptides 2004, 38:311-315.
3. Andreasen N.C., Pressler M., Nopoulos P., Miller D., Ho B.C. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol. Psychiatry 2010, 67:255-262.
4. Annerbrink K., Westberg L., Olsson M., Andersch S., Sjodin I., Holm G., Allgulander C., Eriksson E. Panic disorder is associated with the Val308Iso polymorphism in the hypocretin receptor gene. Psychiatr. Genet. 2011, 21:85-89.
5. Ascher-Svanum H., Stensland M.D., Kinon B.J., Tollefson G.D. Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. J. Psychopharmacol. 2005, 19:110-117.
6. Bagney A., Rodriguez-Jimenez R., Martinez-Gras I., Sanchez-Morla E.M., Santos J.L., Jimenez-Arriero M.A., Lobo A., McGorry P.D., Palomo T. Negative symptoms and executive function in schizophrenia: does their relationship change with illness duration?. Psychopathology 2013, 46:241-248.
7. Berridge C.W., Espana R.A. Hypocretins: waking, arousal, or action?. Neuron 2005, 46:696-698.
8. Blouin A.M., Fried I., Wilson C.L., Staba R.J., Behnke E.J., Lam H.A., Maidment N.T., Karlsson K.A.E., Lapierre J.L., Siegel J.M. Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction. Nat. Commun. 2013, 4:1547.
9. Brundin L., Bjorkqvist M., Petersen A., Traskman-Bendz L. Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. Eur. Neuropsychopharmacol. 2007, 17:573-579.
10. Brundin L., Bjorkqvist M., Traskman-Bendz L., Petersen A. Increased orexin levels in the cerebrospinal fluid the first year after a suicide attempt. J. Affect. Disord. 2009, 113:179-182.
11. Brundin L., Petersen A., Bjorkqvist M., Traskman-Bendz L. Orexin and psychiatric symptoms in suicide attempters. J. Affect. Disord. 2007, 100:259-263.
12. Dalal M.A., Schuld A., Pollmacher T. Lower CSF orexin A (hypocretin-1) levels in patients with schizophrenia treated with haloperidol compared to unmedicated subjects. Mol. Psychiatry 2003, 8:836-837.
13. de Lecea L., Kilduff T.S., Peyron C., Gao X., Foye P.E., Danielson P.E., Fukuhara C., Battenberg E.L., Gautvik V.T., Bartlett F.S., Frankel W.N., van den Pol A.N., Bloom F.E., Gautvik K.M., Sutcliffe J.G. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:322-327.
14. Deutch A.Y., Bubser M. The orexins/hypocretins and schizophrenia. Schizophr. Bull. 2007, 33:1277-1283.
15. Ehrstrom M., Naslund E., Levin F., Kaur R., Kirchgessner A.L., Theodorsson E., Hellstrom P.M. Pharmacokinetic profile of orexin A and effects on plasma insulin and glucagon in the rat. Regul. Pept. 2004, 119:209-212.
16. Emsley R., Rabinowitz J., Torreman M. The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophr. Res. 2003, 61:47-57. RIS-INT-35 Early Psychosis Global Working Group.
17. Fadel J., Bubser M., Deutch A.Y. Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J. Neurosci. 2002, 22:6742-6746.
18. Fadel J., Burk J.A. Orexin/hypocretin modulation of the basal forebrain cholinergic system: role in attention. Brain Res. 2010, 1314:112-123.
19. Goldman-Rakic P.S., Selemon L.D. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr. Bull. 1997, 23:437-458.
20. Hahn B., Shoaib M., Stolerman I.P. Involvement of the prefrontal cortex but not the dorsal hippocampus in the attention-enhancing effects of nicotine in rats. Psychopharmacology (Berlin) 2003, 168:271-279.
21. Harris G.C., Aston-Jones G. Arousal and reward: a dichotomy in orexin function. Trends Neurosci. 2006, 29:571-577.
22. Heaton R.K. The Wisconsin Card Sorting Test Manual 1981, Psychological Assessment Resources Inc., Odessa.
23. Heaton R.K., Chelune G.J., Talley J.L., Kay G.G., Curtis G. Wisconsin Card Sorting Test (WCST). Manual Revised and Expanded 1993, Psychological Assessment Resources Inc., Odessa.
24. Heydendael W., Sharma K., Iyer V., Luz S., Piel D., Beck S., Bhatnagar S. Orexins/hypocretins act in the posterior paraventricular thalamic nucleus during repeated stress to regulate facilitation to novel stress. Endocrinology 2011, 152:4738-4752.
25. Hunter M.D., Ganesan V., Wilkinson I.D., Spence S.A. Impact of modafinil on prefrontal executive function in schizophrenia. Am. J. Psychiatry 2006, 163:2184-2186.
26. Hwu H.G., Chen C.H., Hwang T.J., Liu C.M., Cheng J.J., Lin S.K., Liu S.K., Chi Y.Y., Ou-Young C.W., Lin H.N., Chen W.J. Symptom patterns and subgrouping of schizophrenic patients: significance of negative symptoms assessed on admission. Schizophr. Res. 2002, 56:105-119.
27. Ito N., Yabe T., Gamo Y., Nagai T., Oikawa T., Yamada H., Hanawa T. I.c.v. administration of orexin-A induces an antidepressive-like effect through hippocampal cell proliferation. Neuroscience 2008, 157:720-732.
28. Johnson P.L., Truitt W., Fitz S.D., Minick P.E., Dietrich A., Sanghani S., Traskman-Bendz L., Goddard A.W., Brundin L., Shekhar A. A key role for orexin in panic anxiety. Nat. Med. 2010, 16:111-115.
29. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
30. Koren D., Seidman L.J., Harrison R.H., Lyons M.J., Kremen W.S., Caplan B., Goldstein J.M., Faraone S.V., Tsuang M.T. Factor structure of the Wisconsin Card Sorting Test: dimensions of deficit in schizophrenia. Neuropsychology 1998, 12:289-302.
31. Kukkonen J.P. Physiology of the orexinergic/hypocretinergic system: a revisit in 2012. Am. J. Physiol. Cell Physiol. 2013, 304:C2-C32.
32. Kumari V., Postma P. Nicotine use in schizophrenia: the self medication hypotheses. Neurosci. Biobehav. Rev. 2005, 29:1021-1034.
33. Lambe E.K., Olausson P., Horst N.K., Taylor J.R., Aghajanian G.K. Hypocretin and nicotine excite the same thalamocortical synapses in prefrontal cortex: correlation with improved attention in rat. J. Neurosci. 2005, 25:5225-5229.
34. Lin C.C., Chen W.J., Yang H.J., Hsiao C.K., Tien A.Y. Performance on the Wisconsin Card Sorting Test among adolescents in Taiwan: norms, factorial structure, and relation to schizotypy. J. Clin. Exp. Neuropsychol. 2000, 22:69-79.
35. Lin S.H., Liu C.M., Hwang T.J., Hsieh M.H., Hsiao P.C., Faraone S.V., Tsuang M.T., Hwu H.G., Chen W.J. Performance on the Wisconsin Card Sorting Test in families of schizophrenia patients with different familial loadings. Schizophr. Bull. 2013, 39:537-546.
36. Lutter M., Krishnan V., Russo S.J., Jung S., McClung C.A., Nestler E.J. Orexin signaling mediates the antidepressant-like effect of calorie restriction. J. Neurosci. 2008, 28:3071-3075.
37. Ma X., Wang Q., Sham P.C., Liu X., Rabe-Hesketh S., Sun X., Hu J., Meng H., Chen W., Chen E.Y., Deng W., Chan R.C., Murray R.M., Collier D.A., Li T. Neurocognitive deficits in first-episode schizophrenic patients and their first-degree relatives. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2007, 144B:407-416.
38. Mahendran R., Hendricks M., Chan Y.H. Weight gain in Asian patients on second-generation antipsychotics. Ann. Acad. Med. Singap. 2010, 39:118-121.
39. Meerabux J., Iwayama Y., Sakurai T., Ohba H., Toyota T., Yamada K., Nagata R., Irukayama-Tomobe Y., Shimizu H., Yoshitsugu K., Ohta K., Yoshikawa T. Association of an orexin 1 receptor 408Val variant with polydipsia-hyponatremia in schizophrenic subjects. Biol. Psychiatry 2005, 58:401-407.
40. Meltzer H.Y., Perry E., Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr. Res. 2003, 59:19-27.
41. Moghaddam B., Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J. Neurochem. 1990, 54:1755-1760.
42. Newman L.A., Moll T., McGaughy J.A. The effects of selective orexinergic deafferentation in the medial, prefrontal cortex on sustained attention. Annual meeting of Society for Neuroscience, Program # 839.8 Abstract CD 2007.
43. Nishino S., Ripley B., Mignot E., Benson K.L., Zarcone V.P. CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture. Psychiatry Res. 2002, 110:1-7.
44. Nocjar C., Zhang J., Feng P., Panksepp J. The social defeat animal model of depression shows diminished levels of orexin in mesocortical regions of the dopamine system, and of dynorphin and orexin in the hypothalamus. Neuroscience 2012, 218:138-153.
45. Okubo Y., Suhara T., Suzuki K., Kobayashi K., Inoue O., Terasaki O., Someya Y., Sassa T., Sudo Y., Matsushima E., Iyo M., Tateno Y., Toru M. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997, 385:634-636.
46. Pantelis C., Barber F.Z., Barnes T.R., Nelson H.E., Owen A.M., Robbins T.W. Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr. Res. 1999, 37:251-270.
47. Paolo A.M., Troster A.I., Axelrod B.N., Koller W.C. Construct validity of the WCST in normal elderly and persons with Parkinson's disease. Arch. Clin. Neuropsychol. 1995, 10:463-473.
48. Papuc E., Stelmasiak Z., Grieb P., Pawel G., Rejdak K. CSF hypocretin-1 concentrations correlate with the level of fatigue in multiple sclerosis patients. Neurosci. Lett. 2010, 474:9-12.
49. Pasumarthi R.K., Fadel J. Activation of orexin/hypocretin projections to basal forebrain and paraventricular thalamus by acute nicotine. Brain Res. Bull. 2008, 77:367-373.
50. Peyron C., Tighe D.K., van den Pol A.N., de Lecea L., Heller H.C., Sutcliffe J.G., Kilduff T.S. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 1998, 18:9996-10015.
51. Pierre J.M., Peloian J.H., Wirshing D.A., Wirshing W.C., Marder S.R. A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J. Clin. Psychiatry 2007, 68:705-710.
52. Plaza-Zabala A., Martin-Garcia E., de Lecea L., Maldonado R., Berrendero F. Hypocretins regulate the anxiogenic-like effects of nicotine and induce reinstatement of nicotine-seeking behavior. J. Neurosci. 2010, 30:2300-2310.
53. Rainero I., Ostacoli L., Rubino E., Gallone S., Picci L.R., Fenoglio P., Negro E., Rosso C., De Martino P., De Marchi M., Furlan P.M., Pinessi L. Association between major mood disorders and the hypocretin receptor 1 gene. J. Affect. Disord. 2011, 130:487-491.
54. Rasmussen K., Hsu M.A., Noone S., Johnson B.G., Thompson L.K., Hemrick-Luecke S.K. The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms. Schizophr. Bull. 2007, 33:1291-1297.
55. Rasmussen K., Hsu M.A., Yang Y. The orexin-1 receptor antagonist SB-334867 blocks the effects of antipsychotics on the activity of A9 and A10 dopamine neurons: implications for antipsychotic therapy. Neuropsychopharmacology 2007, 32:786-792.
56. Rotter A., Asemann R., Decker A., Kornhuber J., Biermann T. Orexin expression and promoter-methylation in peripheral blood of patients suffering from major depressive disorder. J. Affect. Disord. 2011, 131:186-192.
57. Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H., Williams S.C., Richarson J.A., Kozlowski G.P., Wilson S., Arch J.R., Buckingham R.E., Haynes A.C., Carr S.A., Annan R.S., McNulty D.E., Liu W.S., Terrett J.A., Elshourbagy N.A., Bergsma D.J., Yanagisawa M. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92:1-696.
58. Sanchez-Torres A.M., Basterra V., Moreno-Izco L., Rosa A., Fananas L., Zarzuela A., Peralta V., Cuesta M.J. Executive functioning in schizophrenia spectrum disorder patients and their unaffected siblings: a ten-year follow-up study. Schizophr. Res. 2013, 143:291-296.
59. Sevy S., Rosenthal M.H., Alvir J., Meyer S., Visweswaraiah H., Gunduz-Bruce H., Schooler N.R. Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J. Clin. Psychiatry 2005, 66:839-843.
60. Smith R.C., Warner-Cohen J., Matute M., Butler E., Kelly E., Vaidhyanathaswamy S., Khan A. Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology 2006, 31:637-643.
61. Staples L.G., Cornish J.L. The orexin-1 receptor antagonist SB-334867 attenuates anxiety in rats exposed to cat odor but not the elevated plus maze: an investigation of Trial 1 and Trial 2 effects. Horm. Behav. 2014, 65:294-300.
62. Strawn J.R., Pyne-Geithman G.J., Ekhator N.N., Horn P.S., Uhde T.W., Shutter L.A., Baker D.G., Geracioti T.D. Low cerebrospinal fluid and plasma orexin-A (hypocretin-1) concentrations in combat-related posttraumatic stress disorder. Psychoneuroendocrinology 2010, 35:1001-1007.
63. Turner D.C., Clark L., Pomarol-Clotet E., McKenna P., Robbins T.W., Sahakian B.J. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 2004, 29:1363-1373.
64. Weinhold S.L., Seeck-Hirschner M., Nowak A., Hallschmid M., Goder R., Baier P.C. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy. Behav. Brain Res. 2014, 262:8-13.
65. Winsky-Sommerer R., Boutrel B., De Lecea L. The role of the hypocretinergic system in the integration of networks that dictate the states of arousal. Drug News Perspect. 2003, 16:504-512.
66. Wirshing D.A., Wirshing W.C., Kysar L., Berisford M.A., Goldstein D., Pashdag J., Mintz J., Marder S.R. Novel antipsychotics: comparison of weight gain liabilities. J. Clin. Psychiatry 1999, 60:358-363.
67. Yeoh J.W., Campbell E.J., James M.H., Graham B.A., Dayas C.V. Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls. Front. Neurosci. 2014, 8:36.